Latest From Aviir Inc.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.
Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.
Corporate venture groups are poised to become one of the main sources of funding for early-stage biotechs thanks to the current economic climate. Even if corporate venture groups invest at the same levels as previous years, some industry veterans believe they could play a role in up to half of the early-stage financings this year, largely because the traditional sources of financing--the public market and venture capital groups flush with cash--have disappeared. And the new vigor of corporate venture offers big benefits to both small biotechs and Big Pharma.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Aviir Inc.
- Senior Management
Douglas S Harrington, MD, CEO
Cynthia French, PhD, CSO
Larry Hansen, Chief Commercial Officer
Najib El Khoury, Dir., International Bus. Dev.
- Contact Info
Phone: (949) 398-6300
9805 Research Dr.
Irvine, CA 92618
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.